InflammationNCT06786910
Effect on Cytokines IL-1ß, TNF-α, IL-4, and Total Bacterial Load of a Composition Comprising Olive Oil, Trimethylglycine and Xylitol Delivered as a Toothpaste
A study testing Toothpaste with olive oil, trimethylglycine and xylitol and Toothpaste without olive oil, trimethylglycine nor xylitol in people with Inflammation and Interleukin-1beta, run by Mucosa Innovations, S.L. at 1 site in Spain.
Trial summary
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and overweight/pre-obese patients. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Inflammation, Interleukin-1beta, TNF-α
- What is being tested?
- Toothpaste with olive oil, trimethylglycine and xylitol and Toothpaste without olive oil, trimethylglycine nor xylitol
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 26 participants
- Where
- 1 siteSpain
- Study dates
- 13 Jun 2022to 15 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- patients attending to a routinary control visit at the University of Barcelona Dental Hospital (HOUB) over 18 years of age;
- who give their informed consent to participate in the study;
- do not have associated medical pathology in ASA III and IV.
Who cannot join
- patients who do not wish to participate in the study;
- allergic to the components of the toothpaste;
- on active antibiotic treatment or having received antibiotic treatment within the past seven days;
- patients presenting pain or acute infections will be excluded as well as ASA III and IV; -
- patients with diabetes and BMI>40 and severe periodontitis will be excluded.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect on Cytokines IL-1ß, TNF-α, IL-4 and Total Bacterial Load of an Oral Topical Composition Comprising Olive Oil, Trymethylglycine and Xylitol: a Randomized Controlled Double-blind Clinical Trial Part of the Stop Dysbiosis Project (SDP)
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and overweight/pre-obese patients. The main question it aims to answer is if 1 month use of a composition under patent protection (patent pending, publication no. EP 4110321 A1 and US 2023/041103 A1) is able to reduce pro-inflammatory cytokines. The inflammatory background common to chronic inflammatory conditions is receiving the focus of research as it is thought to be originated in the overexpression of pro-inflammatory cytokines mainly IL-1ß and TNF-α considered today the link between the high burden of comorbidities associated to inflammation.
Researchers will compare the novel composition to a placebo (placebo toothpaste with same colour and flavour) to see if pro-inflammatory cytokine levels are reduced.
In a randomised double-blind controlled trial participants will be alleatorized to one of two groups, intervention or control. The composition will be delivered via toothpaste onto the oral mucosa in the intervention group while the control group will use a placebo toothpaste with the same characteristics but lacking the composition. All participants will be instructed to brush their teeth 3 times a day for one month without having had a dental cleaning before the start of the study.
Read the detailed description
Barrier integrity plays a pivotal role in the homeostasis of the innate immune system. These barriers, their cells and networks, when intact and inhabited with an eubiotic microbiome, regulate immunity and inflammation, keeping the body in a state of homeostasis and balance with the outcome of health.
External pressure on mucosa and skin barriers from foreign substances and environmental circumstances, provides a changing ground for pro-inflammatory cytokine expression leading to what is known today as metabolic infection and systemic inflammation. Maintained pressure can exceed immune system control mechanisms, resulting in an ungoverned release of a variety of pro-inflammatory cytokines such as IL-1ß and TNF-α, that will further contribute to barrier breakage and to a state of immune dysregulation and inflammation. On the contrary, IL-4 has been ascribed both anti-inflammatory and pro-inflammatory properties.
Periodontal inflammation, the second most frequent contributor to systemic inflammatory load behind obesity, is an important factor upregulating salivary pro-inflammatory cytokines, and offers a practical model to address the complex crosstalk between inflammation and chronic inflammatory diseases.
STUDY DESIGN The current study will be a randomized controlled trial in periodontally healthy patients scheduled for a routine visit at the University of Barcelona (UB), Dental Hospital Barcelona University (HOUB), Bellvitge Campus.
Randomization and masking Patients will be randomly assigned by means of a random assignment sequence generated using Microsoft Office Excel 2019 (Microsoft Corporation, Washington, USA, 2013). A 1:1 distribution will be used to assign participants to either the Intervention Group (IG) or the Control Group (CG).
Intervention group will use an experimental toothpaste containing a novel composition comprising olive oil, trimethylglycine and xylitol. Control group will use a placebo toothpaste. Excipients will be common to both groups. All products will be packaged in white tubes with a label that will identify the number of patient. The product information allocated to each patient will be placed in a sealed envelope, exhibiting exclusively patient allocation number to maintain the integrity of the blinding process. Both, participants and operators will be masked to assignment.
Interventions Participants will be recruited during a routine visit to the University of Barcelona Dental Hospital. All participants from both groups will be attended at the dental clinic at the beginning and at the end of the study. During first visit baseline data will be recovered. Final visit will take place after one month for final data collection.
- First Visit (T0):
Patients will be informed on the study details. Sex and age data will be recovered from medical history. No periodontal treatment, hygiene or profilaxis will be performed to avoid altering subgingival ecosystem. The following data will be recovered:
- Oral mucosa examination
- Decayed, missing and filled teeth (DMFT) index
- O'Leary Plaque Index
- Basic Periodontal Examination: Probing depth and clinical attachment loss
- Sialometry: Unstimulated and stimulated salivary flow were measured
- Salivary pH Unstimulated saliva will be used to cytokine analysis. Samples will be taken with sterile paper points inserted into the gingival sulcus of at least three teeth, preferably from 16, 22, 41, 47 for microbial analysis.
Participant´s weight and height will be recorded and body mass index (BMI) calculated to allow participants classification according to their nutritional status.
At the end of the visit, patients will receive their randomized assigned toothpaste and will be instructed to brush their teeth three times a day and refrain from using any other oral hygiene products. The second and final visit wil be scheduled after 1 month.
II. Second Visit (T1):
The procedure from first visit will be repeated, collecting the same data. Additionally, a visual analogue scale (VAS) will be provided for each patient who will rate ease of use, flavour, satisfaction, acceptance, preference, and recommendation from 0 to 10. Along the duration of the study and during the second and last visit, patients will be asked for any adverse or unwanted side effect. At this time, oral prophylaxis and dental cleaning will be performed.
Methodology:
Cytokine analysis Samples from unstimulated saliva will be sent immediately to the microbiology laboratory of UB Bellvitge Hospital. Samples will be centrifuged (14000 rpm, 10 min, 4ºC), and supernatants stored at -80ºC until determination of TNF-α, IL-1β, and IL-4 concentrations by enzyme linked immunosorbent assay (ELISA). Commercial kits (BioLegend ELISA MaxDeluxe Kit Human TNF, IL-1β e IL-4 and Human TNF, IL-1β e IL-4 Enhanced Sensitivity Flex test BD Cytometric Bead Array) will be used.
Additional analysis Microbiological analysis to assess subgingival total bacterial load will be performed with impregnated paper points that will be placed in a 2 ml cryotube and sent immediately to the microbiology laboratory of UB Bellvitge Hospital, where they will be frozen at -80ºC for further processing by quantitative polymerase chain reaction (real-time qPCR) using TaqMan assay. Total bacteria load, expressed as logarithmic units (log) of colony forming units per mL (cfu/ml), will be determined by amplifying 16S rRNA gene using universal procariotic primers.
Statistical analysis Sample size has been calculated using an α=0.05, a ß=0.2, and a 2-tailed significance level of 95%. Based on data from a pilot study testing the same composition.
Data were analysed with the SPSS Statistics software version 26. Categorical variables were described in frequency and percentage. Numerical variables, according to their distribution, in mean and standard deviation or median and minimum and maximum were expressed. Categorical variables were compared using the chi-square test for sex and t-student test for age. Numerical variables under study (inflammatory markers and bacterial load), having a non-normal distribution, were compared using non-parametric tests. To determine the differences of values between both groups (intervention and control) at the two times evaluated (T0: baseline; T1: after 1 month treatment) the Mann-Whitney U test was used for independent samples. To determine intragroup differences before and after the intervention/control, Wilcoxon's signed range test was used for related samples. A p<0.05 value was considered statistically significant.
For analyzing if there were intragroup differences in salivary flow, Fisher's test for independent samples and the McNemar test for related samples were used. The analysis was limited to two categories of the variable: "Normal" or "Low" (including both "Low" and "Very Low"). Regarding effect size calculation for primary outcomes, since the variables did not follow a normal distribution, non-parametric tests were used. The effect size, represented as r-value was calculated using the absolute value of the Z statistic obtained from the Wilcoxon or Mann-Whitney test, divided by the square root of the sample size (i.e., the number of paired values for related samples or the sum of sample sizes for independent samples).
- Conditions
- Inflammation, Interleukin-1beta, TNF-α, Cytokine Levels, BMI, Chronic Inflammatory Diseases
- Being tested
- Toothpaste with olive oil, trimethylglycine and xylitol, Toothpaste without olive oil, trimethylglycine nor xylitol
- Keywords
- Inflammation, Cytokines, IL-1ß, TNF-α, BMI, Overweight, Dysbiosis, Chronic inflammatory diseases, Pro-inflammatory cytokines, olive oil, trimethylglycine and xylitol
- Medical subject headings
- Inflammation, Dysbiosis, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Toothpaste with olive oil, trimethylglycine and xylitolOther
Composition comprising olive oil, trimethylglycine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
Toothpaste without olive oil, trimethylglycine nor xylitolOther
Composition without olive oil, without trimethylglycine and without xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Toothpaste with olive oil, trimethylglycine and xylitol. Receives: Other: Toothpaste with olive oil, trimethylglycine and xylitol |
| Control group | Placebo comparator | Toothpaste with identical flavour and aspect that experimental toothpaste but without olive oil, without trimethylglycine and without xylitol. Receives: Other: Toothpaste without olive oil, trimethylglycine nor xylitol |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in salivary IL-1ß levels.
Differences between IL-1ß levels before and after the use of the assigned toothpaste for intervention and for control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Changes in salivary TNF-α levels.
Differences between TNF-α levels before and after the use of the assigned toothpaste for intervention and for control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Changes in salivary IL-4 levels.
Differences between IL-4 levels before and after the use of the assigned toothpaste for intervention and for control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Comparison of changes in IL-1ß levels between intervention and control groups.
Each group will show a IL-1ß level at baseline and a IL-1ß level after 1 month use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Comparison of changes in TNF-α levels between intervention and control groups.
Each group will show a TNF-α level at baseline and a TNF-α level after the use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Comparison of changes in IL-4 levels between intervention and control groups.
Each group will show a IL-4 level at baseline and a IL-4 level after the use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Secondary outcomes (3)
Changes in subgingival total bacterial load.
Differences between subgingival total bacterial load at baseline and after the use of the assigned toothpaste for each of both groups.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Clinically assessed parameters at baseline and after the use of the assigned toothpaste.
Bleeding on probing and plaque index, both expressed as percentage, at baseline and after the use of the assigned toothpaste for both groups.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Comparison of changes in cytokine levels, due to the use of the assigned toothpaste, between intervention and control group in patients with BMI>25.
Assessment of cytokine levels at baseline and after 1 month use of the assigned toothpaste will be performed. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group for each cytokine in patients with BMI>25.
Measured: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jan 2025
- Study start13 Jun 2022
- Primary completion15 Sep 2022
- Study completion15 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for InflammationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two toothpastes will be included in the study; one with the novel composition including olive oil, trimethylglycine and xylitol, and one without olive oil, trimethylglycine and xylitol. Both toothpastes, intervention and control, will be identical in aspect and flavour. Subjects are randomnly assigned: Researchers and participants will be blinded.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mucosa Innovations, S.L.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Barcelona
- Responsible party
- Sponsor
- Investigators
- José López-López, Principal investigator, Barcelona University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06786910
- Sponsor's protocol ID
- 03-2022
- Status last verified
- Mar 2025
- First submitted
- 10 Jan 2025
- Last updated
- 10 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23.
PubMed 24275598Hajishengallis G, Chavakis T. Inflammatory memory and comorbidities. Clin Transl Med. 2022 Jul;12(7):e984. doi: 10.1002/ctm2.984. No abstract available.
PubMed 35839318
Study at a glance
From the registry record, last updated by the sponsor on 10 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect on Cytokines IL-1ß, TNF-α, IL-4 and Total Bacterial Load of an Oral Topical Composition Comprising Olive Oil, Trymethylglycine and Xylitol: a Randomized Controlled Double-blind Clinical Trial Part of the Stop Dysbiosis Project (SDP)
- ClinicalTrials.gov ID
- NCT06786910
- Acronym / sponsor ID
- 03-2022
- Conditions
- Inflammation, Interleukin-1beta, TNF-α, Cytokine Levels, BMI, Chronic Inflammatory Diseases
- Keywords
- Inflammation, Cytokines, IL-1ß, TNF-α, BMI, Overweight, Dysbiosis, Chronic inflammatory diseases
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Mucosa Innovations, S.L.Industry (pharma, biotech, devices)
- Collaborators
- University of Barcelona
- Study start
- 13 Jun 2022 (actual)
- Primary completion
- 15 Sep 2022 (actual)
- Study completion
- 15 Sep 2022 (actual)
- First posted
- 22 Jan 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if a novel composition comprising olive oil, trimethylglycine and xylitol, affects salivary levels of IL-1ß, TNF-α and IL-4 in a group of periodontally healthy, normal and overweight/pre-obese patients. The main question it aims to answer is if 1 month use of a composition under patent protection (patent pending, publication no. EP 4110321 A1 and US 2023/041103 A1) is able to reduce pro-inflammatory cytokines. The inflammatory background common to chronic inflammatory conditions is receiving the focus of research as it is thought to be originated in the overexpression of pro-inflammatory cytokines mainly IL-1ß and TNF-α considered today the link between the high burden of comorbidities associated to inflammation.
Researchers will compare the novel composition to a placebo (placebo toothpaste with same colour and flavour) to see if pro-inflammatory cytokine levels are reduced.
In a randomised double-blind controlled trial participants will be alleatorized to one of two groups, intervention or control. The composition will be delivered via toothpaste onto the oral mucosa in the intervention group while the control group will use a placebo toothpaste with the same characteristics but lacking the composition. All participants will be instructed to brush their teeth 3 times a day for one month without having had a dental cleaning before the start of the study.
Detailed description
Barrier integrity plays a pivotal role in the homeostasis of the innate immune system. These barriers, their cells and networks, when intact and inhabited with an eubiotic microbiome, regulate immunity and inflammation, keeping the body in a state of homeostasis and balance with the outcome of health.
External pressure on mucosa and skin barriers from foreign substances and environmental circumstances, provides a changing ground for pro-inflammatory cytokine expression leading to what is known today as metabolic infection and systemic inflammation. Maintained pressure can exceed immune system control mechanisms, resulting in an ungoverned release of a variety of pro-inflammatory cytokines such as IL-1ß and TNF-α, that will further contribute to barrier breakage and to a state of immune dysregulation and inflammation. On the contrary, IL-4 has been ascribed both anti-inflammatory and pro-inflammatory properties.
Periodontal inflammation, the second most frequent contributor to systemic inflammatory load behind obesity, is an important factor upregulating salivary pro-inflammatory cytokines, and offers a practical model to address the complex crosstalk between inflammation and chronic inflammatory diseases.
STUDY DESIGN The current study will be a randomized controlled trial in periodontally healthy patients scheduled for a routine visit at the University of Barcelona (UB), Dental Hospital Barcelona University (HOUB), Bellvitge Campus.
Randomization and masking Patients will be randomly assigned by means of a random assignment sequence generated using Microsoft Office Excel 2019 (Microsoft Corporation, Washington, USA, 2013). A 1:1 distribution will be used to assign participants to either the Intervention Group (IG) or the Control Group (CG).
Intervention group will use an experimental toothpaste containing a novel composition comprising olive oil, trimethylglycine and xylitol. Control group will use a placebo toothpaste. Excipients will be common to both groups. All products will be packaged in white tubes with a label that will identify the number of patient. The product information allocated to each patient will be placed in a sealed envelope, exhibiting exclusively patient allocation number to maintain the integrity of the blinding process. Both, participants and operators will be masked to assignment.
Interventions Participants will be recruited during a routine visit to the University of Barcelona Dental Hospital. All participants from both groups will be attended at the dental clinic at the beginning and at the end of the study. During first visit baseline data will be recovered. Final visit will take place after one month for final data collection.
- First Visit (T0):
Patients will be informed on the study details. Sex and age data will be recovered from medical history. No periodontal treatment, hygiene or profilaxis will be performed to avoid altering subgingival ecosystem. The following data will be recovered:
- Oral mucosa examination
- Decayed, missing and filled teeth (DMFT) index
- O'Leary Plaque Index
- Basic Periodontal Examination: Probing depth and clinical attachment loss
- Sialometry: Unstimulated and stimulated salivary flow were measured
- Salivary pH Unstimulated saliva will be used to cytokine analysis. Samples will be taken with sterile paper points inserted into the gingival sulcus of at least three teeth, preferably from 16, 22, 41, 47 for microbial analysis.
Participant´s weight and height will be recorded and body mass index (BMI) calculated to allow participants classification according to their nutritional status.
At the end of the visit, patients will receive their randomized assigned toothpaste and will be instructed to brush their teeth three times a day and refrain from using any other oral hygiene products. The second and final visit wil be scheduled after 1 month.
II. Second Visit (T1):
The procedure from first visit will be repeated, collecting the same data. Additionally, a visual analogue scale (VAS) will be provided for each patient who will rate ease of use, flavour, satisfaction, acceptance, preference, and recommendation from 0 to 10. Along the duration of the study and during the second and last visit, patients will be asked for any adverse or unwanted side effect. At this time, oral prophylaxis and dental cleaning will be performed.
Methodology:
Cytokine analysis Samples from unstimulated saliva will be sent immediately to the microbiology laboratory of UB Bellvitge Hospital. Samples will be centrifuged (14000 rpm, 10 min, 4ºC), and supernatants stored at -80ºC until determination of TNF-α, IL-1β, and IL-4 concentrations by enzyme linked immunosorbent assay (ELISA). Commercial kits (BioLegend ELISA MaxDeluxe Kit Human TNF, IL-1β e IL-4 and Human TNF, IL-1β e IL-4 Enhanced Sensitivity Flex test BD Cytometric Bead Array) will be used.
Additional analysis Microbiological analysis to assess subgingival total bacterial load will be performed with impregnated paper points that will be placed in a 2 ml cryotube and sent immediately to the microbiology laboratory of UB Bellvitge Hospital, where they will be frozen at -80ºC for further processing by quantitative polymerase chain reaction (real-time qPCR) using TaqMan assay. Total bacteria load, expressed as logarithmic units (log) of colony forming units per mL (cfu/ml), will be determined by amplifying 16S rRNA gene using universal procariotic primers.
Statistical analysis Sample size has been calculated using an α=0.05, a ß=0.2, and a 2-tailed significance level of 95%. Based on data from a pilot study testing the same composition.
Data were analysed with the SPSS Statistics software version 26. Categorical variables were described in frequency and percentage. Numerical variables, according to their distribution, in mean and standard deviation or median and minimum and maximum were expressed. Categorical variables were compared using the chi-square test for sex and t-student test for age. Numerical variables under study (inflammatory markers and bacterial load), having a non-normal distribution, were compared using non-parametric tests. To determine the differences of values between both groups (intervention and control) at the two times evaluated (T0: baseline; T1: after 1 month treatment) the Mann-Whitney U test was used for independent samples. To determine intragroup differences before and after the intervention/control, Wilcoxon's signed range test was used for related samples. A p<0.05 value was considered statistically significant.
For analyzing if there were intragroup differences in salivary flow, Fisher's test for independent samples and the McNemar test for related samples were used. The analysis was limited to two categories of the variable: "Normal" or "Low" (including both "Low" and "Very Low"). Regarding effect size calculation for primary outcomes, since the variables did not follow a normal distribution, non-parametric tests were used. The effect size, represented as r-value was calculated using the absolute value of the Z statistic obtained from the Wilcoxon or Mann-Whitney test, divided by the square root of the sample size (i.e., the number of paired values for related samples or the sum of sample sizes for independent samples).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
- Model description
- Two toothpastes will be included in the study; one with the novel composition including olive oil, trimethylglycine and xylitol, and one without olive oil, trimethylglycine and xylitol. Both toothpastes, intervention and control, will be identical in aspect and flavour. Subjects are randomnly assigned: Researchers and participants will be blinded.
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Other: Toothpaste with olive oil, trimethylglycine and xylitolToothpaste with olive oil, trimethylglycine and xylitol. |
| Control group | Placebo comparator | Other: Toothpaste without olive oil, trimethylglycine nor xylitolToothpaste with identical flavour and aspect that experimental toothpaste but without olive oil, without trimethylglycine and without xylitol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- patients attending to a routinary control visit at the University of Barcelona Dental Hospital (HOUB) over 18 years of age;
- who give their informed consent to participate in the study;
- do not have associated medical pathology in ASA III and IV.
Key exclusion criteria (5 listed)
- patients who do not wish to participate in the study;
- allergic to the components of the toothpaste;
- on active antibiotic treatment or having received antibiotic treatment within the past seven days;
- patients presenting pain or acute infections will be excluded as well as ASA III and IV; -
- patients with diabetes and BMI>40 and severe periodontitis will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Toothpaste with olive oil, trimethylglycine and xylitolComposition comprising olive oil, trimethylglycine and xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month. | Other | Intervention group |
| Toothpaste without olive oil, trimethylglycine nor xylitolComposition without olive oil, without trimethylglycine and without xylitol, formulated as a toothpaste to be delivered topically onto the oral cavity 3 times a day during 1 month. | Other | Control group |
Primary outcome
Changes in salivary IL-1ß levels.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Differences between IL-1ß levels before and after the use of the assigned toothpaste for intervention and for control group.
Changes in salivary TNF-α levels.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Differences between TNF-α levels before and after the use of the assigned toothpaste for intervention and for control group.
Changes in salivary IL-4 levels.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Differences between IL-4 levels before and after the use of the assigned toothpaste for intervention and for control group.
Comparison of changes in IL-1ß levels between intervention and control groups.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Each group will show a IL-1ß level at baseline and a IL-1ß level after 1 month use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
Comparison of changes in TNF-α levels between intervention and control groups.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Each group will show a TNF-α level at baseline and a TNF-α level after the use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
Comparison of changes in IL-4 levels between intervention and control groups.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Each group will show a IL-4 level at baseline and a IL-4 level after the use of the assigned toothpaste. Sense and magnitude of the changes observed for the intervention group will be compared with the changes observed for the control group.
3 secondary outcomes
Changes in subgingival total bacterial load.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Clinically assessed parameters at baseline and after the use of the assigned toothpaste.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Comparison of changes in cytokine levels, due to the use of the assigned toothpaste, between intervention and control group in patients with BMI>25.
Time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Mar 2025.
- Background: PubMed 24275598Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013 Dec 15;25(6):469-84. doi: 10.1016/j.smim.2013.10.008. Epub 2013 Nov 23.
- Background: PubMed 35839318Hajishengallis G, Chavakis T. Inflammatory memory and comorbidities. Clin Transl Med. 2022 Jul;12(7):e984. doi: 10.1002/ctm2.984. No abstract available.
- Individual participant dataSharing planned: Undecided
Related trials for Inflammation
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
RecruitingPhase 4
A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
Infection, Sepsis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
José López-López principal investigator
Barcelona University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Toothpaste with olive oil, trimethylglycine and xylitol and Toothpaste without olive oil, trimethylglycine nor xylitol in people with Inflammation and Interleukin-1beta, run by Mucosa Innovations, S.L. at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in salivary IL-1ß levels. (time frame: T0 refers to the time at which baseline measurements are taken. T1 refers to 30 days.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06786910, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2025.